In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy

The EU Horizon 2020 funded SILICOFCM project (www.silicofcm.eu) will develop a computational platform for in silico clinical trials for familial cardiomyopathies capable of optimizing and testing medical treatment strategies to improve patients outcomes. As a Chief Investigator of a clinical workpackage, Professor Jakovljevic leads an international multicentre phase II clinical trial "Sacubitril/valsartan vs lifestyle in hypertrophic cardiomyopathy" (https://clinicaltrials.gov/ct2/show/NCT03832660).
Total project value €5,559,201.